CoChat
Sign Up
Cited by 560Tissue Engineering and Regenerative MedicinePolymer Surface Interaction StudiesOrthopaedic implants and arthroplasty

Biomaterials/Tissue Interactions: Possible Solutions to Overcome Foreign Body Response

Open access
Morais, Jacqueline M., Papadimitrakopoulos, Fotios, Burgess, Diane J.·2010·The AAPS Journal
DOI 10.1208/s12248-010-9175-3PMC PMC2844517
Open this paper in CoChat — free accountOpen PDF

Abstract

In recent years, a variety of biomaterial implantable devices has been developed. Of particular significance to pharmaceutical sciences is the progress made on the development of drug/implantable device combination products. However, the clinical application of these devices is still a critical issue due to the host response, which results from both the tissue trauma during implantation and the presence of the device in the body. Accordingly, the in vivo functionality and durability of any implantable device can be compromised by the body response to the foreign material. Numerous strategies to overcome negative body reactions have been reported. The aim of this review is to outline some key issues of biomaterial/tissue interactions such as foreign body response and biocompatibility and biocompatibility assessment. In addition, general approaches used to overcome the in vivo instability of implantable devices are presented, including (a) biocompatible material coatings, (b) steroidal and nonsteroidal anti-inflammatory drugs, and (c) angiogenic drugs. In particular, strategies to overcome host response to glucose biosensors are summarized.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1208/s12248-010-9175-3

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 81

  1. Prokop A. Bioartificial organs in the twenty-first century: nano- biological devices. Ann NY Acad Sci. 2001;944:472-90.
  2. Wilson GS, Zhang Y, Reach G, Moatti-Sirat D, Poitout V, Thévenot DR, et al. Progress toward the development of an implantable sensor for glucose. Clin Chem. 1992;38(9):1613-7.
  3. Klonoff DC. Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose meas- urement, the artificial pancreas, and insulin delivery. Pediatr Endocrinol Rev. 2003;1(2):94-100.
  4. Koschwanez HE, Reichert WM. In vitro, in vivo and post explantation testing of glucose-detecting biosensors: current meth- ods and recommendations. Biomaterials. 2007;28(25):3687-703.
  5. Buckingham B, Caswell K, Wilson DM. Real-time continuous glucose monitoring. Curr Opin Endocrinol Diabetes Obes. 2007;14(4):288-95.
  6. Callahan 4th TD, Natale A. Catheter ablation of atrial fibrilla- tion. Med Clin North Am. 2008;92(1):179-201. xii.
  7. Black MM, Drury PJ. Mechanical and other problems of artificial valves. Curr Top Pathol. 1994;86:127-59.
  8. Salgado AJ, Coutinho OP, Reis RL. Bone tissue engineering: state of the art and future trends. Macromol Biosci. 2004;4 (8):743-65.
  9. Matsumoto T, Okazaki M, Nakahira A, Sasaki J, Egusa H, Sohmura T. Modification of apatite materials for bone tissue engineering and drug delivery carriers. Curr Med Chem. 2007;14 (25):2726-33.
  10. Kipshidze NN, Tsapenko MV, Leon MB, Stone GW, Moses JW. Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther. 2005;3(5):953-68.
  11. Williams DF. Tissue-biomaterial interactions. J Mater Sci. 1987;22:3421-45.
  12. Domb A, Maniar M, editors. Site specific drug delivery. New York: Wiley; 1994. p. 27-46.
  13. Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31:81-110.
  14. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocom- patibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials. 2003;24(19):3311-31.
  15. Ratner BA, Horbett TA. Some background concepts. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego: Elsevier; 2004. p. 237.
  16. Anderson JM. Inflammatory response to implants. ASAIO Trans. 1988;34(2):101-7.
  17. Ziats NP, Miller KM, Anderson JM. In vitro and in vivo interactions of cells with biomaterials. Biomaterials. 1988;9(1):5-13.
  18. Schoen FJ, Anderson JM. Host response to biomaterials and their evaluation. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine, 2 nd . San Diego: Elsevier; 2004. p. 293-6.
  19. Sieminski AL, Gooch KJ. Biomaterial-microvasculature inter- actions. Biomaterials. 2000;21(22):2232-41.
  20. Mitchell RN, Cotran RS. Acute and chronic inflammation in Robbins basic pathology. Philadelphia: Saunders; 2002. p. 33-60.
  21. Ratner BD, Bryant SJ. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng. 2004;6:41-75.
  22. Jutila MA. Leukocyte traffic to sites of inflammation. APMIS. 1992;100(3):191-201.
  23. Pober JS, Cotran RS. The role of endothelial cells in inflamma- tion. Transplantation. 1990;50(4):537-44.
  24. Williams GT, Williams WJ. Granulomatous inflammation-a review. J Clin Pathol. 1983;36(7):723-73.
  25. Wahl SM, Wong H, McCartney-Francis N. Role of growth factors in inflammation and repair. J Cell Biochem. 1989;40(2):193-9.
  26. Johnston Jr RB. Current concepts: immunology, monocytes and macrophages. N Engl J Med. 1988;318(12):747-52.
  27. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today. 1991;12(1):17-23.
  28. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991;45(4):319-26.
  29. Labat-Robert J, Bihari-Varga M, Robert L. Extracellular matrix. FEBS Lett. 1990;268(2):386-93.
  30. Anderson JM, Langone JJ. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J Control Release. 1999;57(2):107-13.
  31. Mikos AG, McIntire LV, Anderson JM, Babensee JE. Host response to tissue engineered devices. Adv Drug Deliv Rev. 1998;33(1-2):111-39.
  32. Ratner BD, Northup SJ, Anderson JM. Biological testing of biomaterials. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego: Elsevier; 2004. p. 355-60.
  33. Dekker A, Panfil C, Valdor M, Richter H, Mittermayer Ch, Kirkpatrick CJ. Quantitative methods for in vitro cytotoxicity testing of biomaterials. Cells Mater. 1994;4:101-12.
  34. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res. 1999;45 (3):231-9.
  35. Hoffman AS, Cooper SL, Visser SA, Hergenrother RW, Lamba NMK, Peppas NA, et al. Classes of materials used in medicine. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego: Elsevier; 2004. p. 67-127.
  36. Göpferich A. Polymer degradation and erosion: mechanisms and applications. Eur J Pharm Biopharm. 1996;42(1):1-11.
  37. Shastri VP. Non-degradable biocompatible polymers in medicine: past, present and future. Current Pharm Biotech. 2003;4:331-7.
  38. Shen M, Horbett TA. The effects of surface chemistry and adsorbed proteins on monocyte /macrophage adhesion to chemi- cally modified polystyrene surfaces. J Biomed Mater Res. 2001;57(3):336-45.
  39. Dalsin JL, Hu BH, Lee BP, Messersmith PB. Mussel adhesive protein mimetic polymers for the preparation of nonfouling surfaces. J Am Chem Soc. 2003;125(14):4253-8.
  40. de Vos P, Hoogmoed CG, Busscher HJ. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J Biomed Mater Res. 2002;60(2):252-9.
  41. Uchegbu IF, Schätzlein AG, Tetley L, Gray AI, Sludden J, Siddique S, et al. Polymeric chitosan-based vesicles for drug delivery. J Pharm Pharmacol. 1998;50(5):453-8.
  42. Borchard G, Junginger HE. Modern drug delivery applications of chitosan. Adv Drug Deliv Rev. 2001;52(2):103.
  43. Sano A, Hojo T, Maeda M, Fujioka K. Protein release from collagen matrices. Adv Drug Deliv Rev. 1998;31(3):247-66.
  44. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev. 2003;55 (12):1613-29.
  45. Draye JP, Delaey B, van de Voorde A, van Den Bulcke A, de Reu B, Schacht E. In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films. Bioma- terials. 1998;19(18):1677-87.
  46. Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst. 1998;15(5):513-55.
  47. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials. 1996;17(2):93- 102.
  48. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev. 1997;28 (1):5-24.
  49. Espadas-Torre C, Meyerhoff ME. Thrombogenic properties of untreated and poly(ethylene oxide)-modified polymeric matrices useful for preparing intra-arterial ion-selective electrodes. Anal Chem. 1995;67(18):3108-14.
  50. Paradossi G, Cavalieri F, Chiessi E, Spagnoli C, Cowman MK. Poly(vinyl alcohol) as versatile biomaterial for potential bio- medical applications. J Mater Sci Mater Med. 2003;14(8):687-91.
  51. Maruoka S, Matsuura T, Kawasaki K, Okamoto M, Yoshiaki H, Kodama M, et al. Biocompatibility of poly-vinyl-alcohol gel as a vitreous substitute. Curr Eye Res. 2006;31(7-8):599-606.
  52. Ravin AG, Olbrich KC, Levin LS, Usala AL, Klizman B. Long- and short-term effects of biological hydrogels on capsule micro- vascular density around implants in rats. J Biomed Mater Res. 2001;58:313-8.
  53. Quinn CA, Connor RE, Heller A. Biocompatible, glucose- permeable hydrogel for in situ coating of implantable biosensors. Biomaterials. 1997;18(24):1665-70.
  54. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res. 2002;61(2):180-7.
  55. Patil SD, Papadimitrakopoulos F, Burgess DJ. Dexamethasone- loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alco- hol) hydrogel composite coatings for inflammation control. Diabetes Technol Ther. 2004;6(6):887-97.
  56. Galeska I, Kim TK, Patil SD, Bhardwaj U, Chatttopadhyay D, Papadimitrakopoulos F, et al. Controlled release of dexametha- sone from PLGA microspheres embedded within polyacid- containing PVA hydrogels. AAPS J. 2005;7(1):E231-40.
  57. Norton LW, Tegnell E, Topored SS, Reichert WM. In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coat- ings. Biomaterials. 2005;26(16):3285-97.
  58. Norton LW, Koschwanez HE, Wisniewski NA, Klitzman B, Reichert WM. Vascular endothelial grown factor and dexame- thasone release from non-fouling sensor coating affect the foreign body response. J Bio Mater Res A. 2007;81(4):858-69.
  59. Patil SD, Papadimitrakopouos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release. 2007;117:68-79.
  60. Bhardwaj U, Radhacirsshana S, Papadimitrakopoulos F, Burgess DJ. PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. Int J Pham. 2010;484:78-86.
  61. Perreti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation. 2000;7:147-61.
  62. Strecker EP, Gabelmann A, Boos I, Lucas C, Xu Z, Haberstroh J, et al. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Cardiovasc Intervent Radiol. 1998;21 (6):487-96.
  63. Ronneberger B, Kissel T, Anderson JM. Biocompatibility of ABA triblock copolymer microparticles consisting of poly(L- lactic-co-glycolic-acid) A-blocks attached to central poly(oxy- ethylene) B-blocks in rats after intramuscular injection. Eur J Pharm Biopharm. 1997;43:19-28.
  64. Daugherty AL, Cleland JL, Duenas EM, Mrsny RJ. Pharmaco- logical modulation of the tissue response to implanted polylactic- co-glycolic acid microspheres. Eur J Pharm Biopharm. 1997;44 (1):89-102.
  65. Lunsford L, McKeever U, Eckstein V, Hedley ML. Tissue distribution and persistence in mice of plasmid DNA encapsu- lated in a PLGA-based microsphere delivery vehicle. J Drug Target. 2000;8(1):39-50.
  66. Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/ PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials. 2002;23: 1649-56.
  67. Kyrolainen M, Rigsby P, Eddy S, Vadgama P. Bio-/hemocompat- ibility: implications and outcomes for sensors? Acta Anaesthesiol Scand Suppl. 1995;104:55-60.
  68. Gerritsen M, Jansen JA, Kros A, Vriezema DM, Sommerdijk NA, Nolte RJ, et al. Influence of inflammatory cells and serum on the performance of implantable glucose sensors. J Biomed Mater Res. 2001;54(1):69-75.
  69. Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angio- genesis in a novel covalently cross-linked gel of heparin and alginate. J Biomed Mater Res. 2001;56:216-21.
  70. Ward WK, Quinn MJ, Wood MD, Tiekotter KL, Pidikiti S, Gallagher JA. Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF)? Biosens Bioelec- tron. 2003;19:155-63.
  71. Kedem A, Perets A, Gamlieli-Bonshtein I, Dvir-Ginzberg M, Mizrahi S, Cohen S. Vascular endothelial growth factor-releasing enhance vascularization and engraftment of hepatocytes trans- planted on liver lobes. Tissue Eng. 2005;11:715-22.
  72. Gaytan F, Morales C, Bellido C, Sanchez-Criado JE. Selective apoptosis of luteal endothelial cells in dexamethasone-treated rats leads to ischemic necrosis of luteal tissue. Biol Reprod. 2002;66:232-40.
  73. Halaby IA, Lyden SP, Davies MG, Roztocil E, Salamone LJ, Brooks AI. Glucocorticoid-regulated VEGF expression in ische- mic skeletal muscle. Molec Ther. 2002;5(3):300-6.
  74. Reach G, Wilson GS. Can continuous glucose monitoring be used for the treatment of diabetes? Anal Chem. 1992;64 (6):381A-6.
  75. Rebrin K, Fischer U, Hahn von Dorsche H, von Woetke T, Abel P, Brunstein E. Subcutaneous glucose monitoring by means of electrochemical sensors: fiction or reality. J Biomed Eng. 1992;14 (1):33-40.
  76. Bobbioni-Harsch E, Rohner-Jeanrenaud F, Koudelka M, de Rooij N, Jeanrenaud B. Lifespan of subcutaneous glucose sensors and their performances during dynamic glycemia changes in rats. J Biomed Eng. 1993;15(6):457-63.
  77. Gilligan BJ, Shults MC, Rhodes RK, Updike SJ. Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care. 1994;17(8):882-7.
  78. Gerritsen M, Kros A, Srpakel V, Lutterman JA, Notle RJM, Jansen JA. Biocompatibility evaluation of sol-gel coating for subcutaneously implantable glucose sensors. Biomaterials. 2000;21:71-8.
  79. Yu B, Wang C, Ju YM, West L, Harmon J, Moussy Y, et al. Use of hydrogel coating to improve the performance of implanted glucose sensors. Biosens Bioelectron. 2008;23(8):1278-84.
  80. Rigby G, Ahmed S, Horseman G, Vadgama P. In vivo glucose monitoring with open microflow-influences of fluid composi- tion and preliminary evaluation in man. Anal Chim Acta. 1999;385:23-32.
  81. Bhardwaj U, Papadimitrakopoulos F, Burgess DJ. A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors. J Diabetes Sci Tech. 2008;2 (6):1016-29.

Cited by

Sorted by citations

Authors
Morais, J. M., Papadimitrakopoulos, F., & Burgess, D. J.
Affiliations
University of Connecticut (US)
Corresponding author
Burgess, Diane J.
ORCID
Burgess, Diane J.
Venue
The AAPS Journal
Publisher
Springer Science and Business Media LLC
Published
2010-02-09
Volume
12
Issue
2
Pages
188-196
ISSN
1550-7416 (ISSN-L)
DOI
10.1208/s12248-010-9175-3
PMC
PMC2844517
OpenAlex
W2016578709
Cited by
560
References
7
Citations by year
2026: 13 · 2025: 24 · 2024: 28 · 2023: 36 · 2022: 29 · 2021: 44 · 2020: 61 · 2019: 60 · 2018: 47 · 2017: 41 · 2016: 43 · 2015: 44 · 2014: 28 · 2013: 18 · 2012: 22
FWCI
3.52
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • The AAPS Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R21HL090458, R21HL90458-01)
  • Telemedicine and Advanced Technology Research Center
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Materials Science › Surfaces, Coatings and Films › Polymer Surface Interaction Studies
  • Health Sciences › Medicine › Surgery › Orthopaedic implants and arthroplasty
Keywords
foreign body reaction, biomaterial-tissue interaction, biocompatibility, biocompatibility assessment, implantable drug delivery, biocompatible coatings, anti-inflammatory agents, glucose biosensor, host response to implants
MeSH terms
Animals, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Biocompatible Materials, Blood Glucose, Dexamethasone, Foreign-Body Reaction, Humans, Materials Testing, Biosensing Techniques, Drug Delivery Systems, Coated Materials, Biocompatible, Hydrogels, Vascular Endothelial Growth Factor A, Angiogenesis Inducing Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review